Martingale Asset Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.49M Sell
222,931
-60,102
-21% -$1.08M 0.11% 194
2026
Q2
$4.9M Buy
283,033
+22,722
+9% +$311K 0.12% 188
2026
Q1
$3.24M Buy
260,311
+50,465
+24% +$678K 0.08% 240
2025
Q4
$2.64M Buy
209,846
+9,643
+5% +$110K 0.07% 259
2025
Q3
$2M Buy
200,203
+45,916
+30% +$412K 0.05% 317
2025
Q2
$1.25M Buy
154,287
+2
+0% +$15 0.03% 416
2025
Q1
$1.29M Buy
154,285
+4,637
+3% +$38.7K 0.03% 400
2024
Q4
$1.19M Buy
149,648
+53,944
+56% +$453K 0.03% 435
2024
Q3
$796K Buy
95,704
+21
+0% +$164 0.02% 522
2024
Q2
$608K Hold
95,683
– – 0.01% 563
2024
Q1
$580K Buy
+95,683
New +$540K 0.01% 591

Other funds holding AMRX

Martingale Asset Management's AMRX Position: Q3 2026 in Review

Martingale Asset Management reduced its Amneal Pharmaceuticals (AMRX) stake by 21% in Q3 2026, selling an estimated $1.08M and leaving 222,931 shares worth $4.49M. The position accounts for 0.11% of the portfolio, ranked #194.

Martingale Asset Management first reported a position in AMRX in Q1 2024 and has held it in 11 quarters since. The position peaked at $4.9M in Q2 2026. 334 funds tracked by Wall St. Rank hold AMRX as of Q3 2026.

  • Martingale Asset Management held 222,931 shares of Amneal Pharmaceuticals worth $4.49M as of Q3 2026.
  • Martingale Asset Management sold 60,102 Amneal Pharmaceuticals shares in Q3 2026, an estimated $1.08M.
  • Amneal Pharmaceuticals made up 0.11% of Martingale Asset Management's portfolio in Q3 2026, its #194 holding.
  • Martingale Asset Management first reported a position in Amneal Pharmaceuticals in Q1 2024 and has held it in 11 quarters since.
  • Martingale Asset Management's Amneal Pharmaceuticals position peaked at $4.9M in Q2 2026.
  • 334 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2026.

Based on Martingale Asset Management's 13F filing for Q3 2026, filed 12 Nov 2026.